Endo, Watson Settle Litigation Over Opana ER Generic

Law360, New York (October 7, 2010, 4:19 PM EDT) -- Endo Pharmaceuticals Inc. has resolved litigation against Watson Pharmaceuticals Inc. over Watson's proposed generic version of the painkiller Opana ER, with Endo granting Watson a royalty-free license to U.S. patents covering the drug.

Under the terms of the settlement, Watson will have the right to launch its generic version on Sept. 15, 2012, or earlier under certain circumstances.

While settlement documents have not yet been filed in the U.S. District Court for the District of New Jersey, where the suit is pending, representatives for both sides...
To view the full article, register now.